Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients ≥ 18 years of age.~2. ECOG 0, 1, or 2.~3. Have been diagnosed with Ph+ CML-CP and receiving imatinib therapy.~4. Patients with suboptimal molecular response to imatinib treatment continued for at least 18 months (first line therapy)~   Suboptimal molecular response defined as all of the following conditions:~  1. Patients who have achieved CCyR (0% Ph+ chromosomes).~  2. Patients who don't achieve MMR (MMR defined as BCR-ABL/ABL ratio of ≤ 0.1% on the International Scale as detected by RQ-PCR).~   The treatment with imatinib defined as:~   Dose of 300 mg or higher daily must be maintained for a minimum of 3 months prior to study entry.~5. Patients who meet the following laboratory tests criteria:~   1. total bilirubin \< 1.5 x ULN,~  2. SGOT and SGPT \< 2.5 x ULN,~  3. creatinine \< 1.5 x ULN,~  4. Serum amylase and lipase ≤ 1.5 x ULN,~  5. Alkaline phosphatase ≤ 2.5 x ULN unless considered tumor related.~  6. Serum potassium, phosphorus, magnesium and calcium ≥ LLN or correctable with supplements prior to the first dose of study drug.~6. Written informed consent prior to any study related screening procedures being performed.~Exclusion Criteria:~1. Prior accelerated phase or blast crisis CML.~2. Previously documented T315I mutations.~3. Presence of chromosomal abnormalities other than Ph+.~4. Previous treatment with any other tyrosine kinase inhibitor except imatinib.~5. Impaired cardiac function including any one of the following:~   1. Complete left bundle branch block~  2. Congenital long QT syndrome or family history of long QT syndrome~  3. History of or presence of significant ventricular or atrial tachyarrhythmias~  4. Clinically significant resting brachycardia (\<50 bpm)~  5. QTcF \> 450 msec on screening ECG~  6. Use of a ventricular-paced pacemaker~  7. Myocardial infarction during the last 12 months~  8. Other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, unstable angina).~6. Treatment with strong CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St John's Wort), and the treatment cannot be discontinued or switched to a different medication prior to starting study drug. See Section 6.4.3 for complete list of these medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nilotinib (Type: EXPERIMENTAL): 400 mg BID

Based on this trial design, predict the completion outcome and termination type (if applicable).